<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12475384</article-id><article-id pub-id-type="pmcid-ver">PMC12475384.1</article-id><article-id pub-id-type="pmcaid">12475384</article-id><article-id pub-id-type="pmcaiid">12475384</article-id><article-id pub-id-type="pmid">41006697</article-id><article-id pub-id-type="doi">10.1038/s41598-025-18385-0</article-id><article-id pub-id-type="publisher-id">18385</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Risk factors for postoperative recurrence of differentiated thyroid cancer: a retrospective study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Han</surname><given-names initials="S">Shuo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yang</surname><given-names initials="Y">Yanqing</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yimaer</surname><given-names initials="W">Wufuer</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abudureheman</surname><given-names initials="D">Dilixiati</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Wang</surname><given-names initials="H">Huguo</given-names></name><address><email>xjxjwhg@163.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02qx1ae98</institution-id><institution-id institution-id-type="GRID">grid.412631.3</institution-id><institution>Department of Vascular and Thyroid Surgery, </institution><institution>The First Affiliated Hospital of Xinjiang Medical University, </institution></institution-wrap>&#220;r&#252;mqi, 830000 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01v83yg31</institution-id><institution-id institution-id-type="GRID">grid.459924.7</institution-id><institution>Department of Ultrasound Diagnosis, </institution><institution>Jiyang District People&#8217;s Hospital, </institution></institution-wrap>Jinan, 25000 China </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478255</issue-id><elocation-id>33140</elocation-id><history><date date-type="received"><day>13</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>1</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>26</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 18:25:14.327"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2025_Article_18385.pdf"/><abstract id="Abs1"><p id="Par1">To investigate the risk factors for recurrence in patients with differentiated thyroid cancer (DTC) following surgery and to provide guidance for reducing the risk of recurrence. The clinical data of 1,118 patients with DTC who underwent surgical treatment at the First Affiliated Hospital of Xinjiang Medical University from June 2019 to June 2021 were retrospectively analyzed. The patients were categorized into two groups: the recurrence group and the non-recurrence group, based on the presence or absence of recurrence. A univariate analysis was conducted on the patient data, followed by a Cox multivariate analysis to identify the risk factors for recurrence in patients with DTC after surgery. Among the eligible patients with DTC, there were 865 females and 253 males, with ages ranging from 15 to 77 years. The follow-up period lasted between 36 and 60 months, during which 46 patients experienced a recurrence. The Cox multivariate regression model analysis indicated that male gender, tumor size, multifocal tumors, central lymph node metastasis, lateral neck lymph node metastasis, and BRAF V600E gene mutation were independent risk factors for the recurrence of DTC (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05). In contrast, bilateral thyroid lobe resection was identified as an independent protective factor against the recurrence of DTC (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05). Male gender, large tumor size, multifocal tumors, neck lymph node metastasis, and BRAF V600E gene mutation are the primary risk factors for the recurrence of DTC following surgery.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-025-18385-0.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Differentiated thyroid cancer(DTC)</kwd><kwd>Recurrence</kwd><kwd>Risk factors</kwd><kwd>Cox multivariate retrospective analysis</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Thyroid cancer</kwd><kwd>Cancer models</kwd><kwd>Endocrine system and metabolic diseases</kwd><kwd>Clinical trials</kwd><kwd>Cancer</kwd><kwd>Surgical oncology</kwd></kwd-group><funding-group><award-group><funding-source><institution>the Health Commission of the Xinjiang Uygur Autonomous Region of China</institution></funding-source><award-id>TSYC202401A062</award-id><award-id>TSYC202401A062</award-id><award-id>TSYC202401A062</award-id><award-id>TSYC202401A062</award-id><award-id>TSYC202401A062</award-id><principal-award-recipient><name name-style="western"><surname>Han</surname><given-names>Shuo</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Yanqing</given-names></name><name name-style="western"><surname>Abudureheman</surname><given-names>Dilixiati</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Huguo</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Thyroid cancer is the most common malignancy of the endocrine system worldwide, ranking seventh in incidence among all cancers<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. In China, its epidemiological significance is particularly notable: recent data indicate that thyroid cancer is the fourth most frequently diagnosed cancer in women and the leading cancer type among women under 30 years of age<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. The predominant pathological subtype, differentiated thyroid cancer (DTC)--which includes papillary (PTC) and follicular (FTC) carcinomas&#8211;generally has favorable outcomes, with 5-year survival rates exceeding 98.5%<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>.</p><p id="Par3">Despite this optimistic prognosis, postoperative recurrence remains a significant clinical challenge. Studies report recurrence rates as high as 10&#8211;30% over long-term follow-up<sup><xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR6">6</xref></sup>, necessitating secondary interventions that substantially affect patients&#8217; quality of life and increase healthcare burdens. Current risk stratification models, such as those endorsed by the American Thyroid Association (ATA)<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>, incorporate factors like tumor size, lymph node metastasis, and extrathyroidal extension. However, these models have limitations in precision. For instance, the prognostic significance of molecular markers (e.g., BRAF V600E), demographic variables (e.g., gender disparities), and the extent of surgery remain incompletely defined, particularly in ethnically diverse populations like those in Western China.</p><p id="Par4">This study addressed gaps in the existing literature or confirmed previous findings through the following approaches:</p><p id="Par5">
<list list-type="bullet"><list-item><p id="Par6">Evaluating understudied risk factors&#8212;including multifocality, BRAF V600E mutation status, and the extent of gland resection&#8212;alongside conventional clinicopathological variables.</p></list-item><list-item><p id="Par7">Providing region-specific data from a large cohort in Xinjiang, China, where demographic and environmental factors may affect recurrence patterns.</p></list-item><list-item><p id="Par8">Developing a clinically actionable nomogram to quantify individualized recurrence risk, thereby enabling tailored surveillance and treatment.</p></list-item></list>
</p><p id="Par9">By integrating these elements, our work aims to enhance postoperative management strategies and reduce recurrence by enabling the early identification of high-risk patients.</p></sec><sec id="Sec2"><title>Results</title><sec id="Sec3"><title>Analysis of recurrence</title><p id="Par10">The follow-up period extends from the day of the patient&#8217;s surgery until June 30, 2024, with a follow-up duration of 36 to 60 months. Among 1,118 cases of DTC patients, 46 cases experienced recurrence during the follow-up period, with the time interval from surgery to recurrence ranging from 3 to 59 months. Based on recurrence status, patients were categorized into two groups: the recurrence group (46 cases) and the non-recurrence group (1,072 cases). During the early postoperative period, the frequency of outpatient follow-up visits was relatively high. Visits were conducted at 1 month, 3 months and 6 months after the operation. Laboratory blood tests were performed at 1 month and 3 months, and blood tests combined with ultrasound examinations were conducted at 6 months. Subsequently, telephone follow-ups were conducted every 3 months, and outpatient follow-ups were combined with blood tests and ultrasound examinations every 6 months. During the outpatient follow-ups, detailed physical examinations were also conducted for the patients. For patients with suspicious recurrence suggested by routine ultrasound, further puncture biopsy was performed. For patients with malignant pathology results from the puncture biopsy, secondary surgical treatment was carried out.The postoperative routine pathological diagnosis of malignancy confirmed the recurrence.</p><p id="Par11">For patients with confirmed recurrence, RAI treatment was evaluated. Endocrine treatment was more standardized. The follow-up frequency was higher than that of patients without recurrence within 1 year after the operation. After outpatient follow-up 1 month after surgery, outpatient follow-up every 3 months, blood sampling and ultrasound examination were performed, and the amount of TSH inhibition therapy was adjusted in time. 1 year later, telephone follow-up was performed every 3 months, and outpatient follow-up was performed every 6 months.</p></sec><sec id="Sec4"><title>Chi-square test for patients with DTC</title><p id="Par12">Patients in the recurrence group and the non-recurrence group exhibited statistically significant differences in gender, tumor diameter, number of tumor lesions, cervical lymph node metastasis status, local tumor invasion, extent of gland resection, BRAF V600E gene mutation, and postoperative serum Tg levels (all <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05). However, there were no statistically significant differences in age, BMI, tumor location, pathological stage, presence of HT, preoperative serum Tg, or preoperative and postoperative serum TSH, Tgab, and TPOab levels between the recurrence and non-recurrence groups (all <italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05). Please refer to Table&#160;<xref rid="Tab1" ref-type="table">1</xref> for further details.</p><p id="Par13">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Comparison of basic information and clinical characteristics of patients [<italic toggle="yes">M</italic>(<italic toggle="yes">P</italic>25, <italic toggle="yes">P</italic>75), n(%)]</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variable</th><th align="left" colspan="1" rowspan="1">Non-recurrence<break/>group</th><th align="left" colspan="1" rowspan="1">Recurrence<break/>group</th><th align="left" colspan="1" rowspan="1">Z/&#967;2</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">P</italic>
</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Gender</td><td align="left" colspan="2" rowspan="1"/><td char="." align="char" colspan="1" rowspan="1">7.460</td><td char="." align="char" colspan="1" rowspan="1">0.006</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Female</td><td align="left" colspan="1" rowspan="1">837(78.1)</td><td align="left" colspan="1" rowspan="1">28(60.9)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Male</td><td align="left" colspan="1" rowspan="1">235(21.9)</td><td align="left" colspan="1" rowspan="1">18(39.1)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><p>Age of first</p><p>operation</p></td><td align="left" colspan="1" rowspan="1">46(36,53)</td><td align="left" colspan="1" rowspan="1">41(36,51)</td><td char="." align="char" colspan="1" rowspan="1">-1.374</td><td char="." align="char" colspan="1" rowspan="1">0.169</td></tr><tr><td align="left" colspan="1" rowspan="1">BMI</td><td align="left" colspan="1" rowspan="1">24(22,27)</td><td align="left" colspan="1" rowspan="1">25(22,27)</td><td char="." align="char" colspan="1" rowspan="1">-0.09</td><td char="." align="char" colspan="1" rowspan="1">0.928</td></tr><tr><td align="left" colspan="1" rowspan="1">Tumor diameter</td><td align="left" colspan="1" rowspan="1">0.7(0.5,1.1)</td><td align="left" colspan="1" rowspan="1">1.7(1.3,2)</td><td char="." align="char" colspan="1" rowspan="1">-7.403</td><td char="." align="char" colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">Tumor location</td><td char="." align="char" colspan="1" rowspan="1">3.540</td><td char="." align="char" colspan="1" rowspan="1">0.060</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Unilateral thyroid</td><td align="left" colspan="1" rowspan="1">767(71.5)</td><td align="left" colspan="1" rowspan="1">27(58.7)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Bilateral thyroid</td><td align="left" colspan="1" rowspan="1">305(28.5)</td><td align="left" colspan="1" rowspan="1">19(41.3)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><p>Number of tumor</p><p>lesions</p></td><td align="left" colspan="1" rowspan="1">1(1,2)</td><td align="left" colspan="1" rowspan="1">2(1,3)</td><td char="." align="char" colspan="1" rowspan="1">-3.627</td><td char="." align="char" colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="3" rowspan="1">TNM stage</td><td char="." align="char" colspan="1" rowspan="1">0.048</td><td char="." align="char" colspan="1" rowspan="1">0.316</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;I, II</td><td align="left" colspan="1" rowspan="1">1064(99.3)</td><td align="left" colspan="1" rowspan="1">45(97.8)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;III, IV</td><td align="left" colspan="1" rowspan="1">8(0.7)</td><td align="left" colspan="1" rowspan="1">1(2.2)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="3" rowspan="1">Central lymph node metastasis</td><td char="." align="char" colspan="1" rowspan="1">24.004</td><td char="." align="char" colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">666(62.1)</td><td align="left" colspan="1" rowspan="1">12(26.1)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">406(37.9)</td><td align="left" colspan="1" rowspan="1">34(73.9)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="3" rowspan="1">Lateral lymph node metastasis</td><td char="." align="char" colspan="1" rowspan="1">69.217</td><td char="." align="char" colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">1003(93.6)</td><td align="left" colspan="1" rowspan="1">27(58.7)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">69(6.40)</td><td align="left" colspan="1" rowspan="1">19(41.3)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="3" rowspan="1">Local invasion</td><td char="." align="char" colspan="1" rowspan="1">7.325</td><td char="." align="char" colspan="1" rowspan="1">0.007</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">978(91.2)</td><td align="left" colspan="1" rowspan="1">36(78.3)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">94(8.80)</td><td align="left" colspan="1" rowspan="1">10(21.7)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="3" rowspan="1">Combined with HT</td><td char="." align="char" colspan="1" rowspan="1">0.844</td><td char="." align="char" colspan="1" rowspan="1">0.358</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">875(81.6)</td><td align="left" colspan="1" rowspan="1">40(87.0)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">197(18.4)</td><td align="left" colspan="1" rowspan="1">6(13.0)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="3" rowspan="1">Extent of gland resection</td><td char="." align="char" colspan="1" rowspan="1">8.690</td><td char="." align="char" colspan="1" rowspan="1">0.013</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>&#160;Bilateral total</p><p>thyroidectomy</p></td><td align="left" colspan="1" rowspan="1">738(68.8)</td><td align="left" colspan="1" rowspan="1">22(47.8)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><p>&#160;Subtotal</p><p>thyroidectomy</p></td><td align="left" colspan="1" rowspan="1">57(5.40)</td><td align="left" colspan="1" rowspan="1">3(6.5)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><p>&#160;Unilateral</p><p>lobectomy</p></td><td align="left" colspan="1" rowspan="1">277(25.8)</td><td align="left" colspan="1" rowspan="1">21(45.7)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="3" rowspan="1">Radioiodine therapy</td><td char="." align="char" colspan="1" rowspan="1">7.670</td><td char="." align="char" colspan="1" rowspan="1">0.006</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">661(61.7)</td><td align="left" colspan="1" rowspan="1">19(41.3)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">411(38.3)</td><td align="left" colspan="1" rowspan="1">27(58.7)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="3" rowspan="1">BRAF V600E gene expression</td><td char="." align="char" colspan="1" rowspan="1">10.073</td><td char="." align="char" colspan="1" rowspan="1">0.002</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;No</td><td align="left" colspan="1" rowspan="1">411(38.3)</td><td align="left" colspan="1" rowspan="1">7(15.2)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#160;Yes</td><td align="left" colspan="1" rowspan="1">661(61.7)</td><td align="left" colspan="1" rowspan="1">39(84.8)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><p>Preoperative serum</p><p>TSH levels</p></td><td align="left" colspan="1" rowspan="1">2.34(1.58,3.52)</td><td align="left" colspan="1" rowspan="1">2.19(1.44,3.66)</td><td char="." align="char" colspan="1" rowspan="1">-0.156</td><td char="." align="char" colspan="1" rowspan="1">0.876</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Preoperative serum</p><p>Tg levels</p></td><td align="left" colspan="1" rowspan="1">9.46(3.93,19.45)</td><td align="left" colspan="1" rowspan="1">7.07(2.97,18.16)</td><td char="." align="char" colspan="1" rowspan="1">-0.509</td><td char="." align="char" colspan="1" rowspan="1">0.610</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Preoperative serum</p><p>Tgab levels</p></td><td align="left" colspan="1" rowspan="1">19.33(14.27,70.44)</td><td align="left" colspan="1" rowspan="1">16.29(12.72,38)</td><td char="." align="char" colspan="1" rowspan="1">-1.175</td><td char="." align="char" colspan="1" rowspan="1">0.240</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Preoperative serum</p><p>TPOab levels</p></td><td align="left" colspan="1" rowspan="1">12.43(9,20.17)</td><td align="left" colspan="1" rowspan="1">13.9(9.95,21.49)</td><td char="." align="char" colspan="1" rowspan="1">-1.061</td><td char="." align="char" colspan="1" rowspan="1">0.289</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Postoperative serum</p><p>TSH levels</p></td><td align="left" colspan="1" rowspan="1">0.98(0.23,2.79)</td><td align="left" colspan="1" rowspan="1">1.42(0.14,5.01)</td><td char="." align="char" colspan="1" rowspan="1">-0.623</td><td char="." align="char" colspan="1" rowspan="1">0.534</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Postoperative serum</p><p>Tg levels</p></td><td align="left" colspan="1" rowspan="1">0.46(0.04,4.61)</td><td align="left" colspan="1" rowspan="1">4(0.81,11.26)</td><td char="." align="char" colspan="1" rowspan="1">-4.085</td><td char="." align="char" colspan="1" rowspan="1">&lt;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Postoperative serum</p><p>Tgab levels</p></td><td align="left" colspan="1" rowspan="1">19.22(14.55,47.95)</td><td align="left" colspan="1" rowspan="1">16.84(13.25,32.6)</td><td char="." align="char" colspan="1" rowspan="1">-1.408</td><td char="." align="char" colspan="1" rowspan="1">0.159</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Postoperative serum</p><p>TPOab levels</p></td><td align="left" colspan="1" rowspan="1">12.35(9,20.27)</td><td align="left" colspan="1" rowspan="1">12.22(8.26,16.12)</td><td char="." align="char" colspan="1" rowspan="1">-1.211</td><td char="." align="char" colspan="1" rowspan="1">0.226</td></tr><tr><td align="left" colspan="1" rowspan="1">Follow-up time</td><td align="left" colspan="1" rowspan="1">47(41,53.5)</td><td align="left" colspan="1" rowspan="1">31.5(11,49)</td><td char="." align="char" colspan="1" rowspan="1">-4.855</td><td char="." align="char" colspan="1" rowspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><p>*BMI: Body Mass Index. *HT: Hashimoto&#8217;s thyroiditis.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec5"><title>Univariate Cox regression analysis of postoperative recurrence in patients with DTC</title><p id="Par14">Univariate analysis revealed that patients&#8217; gender, tumor diameter, number of tumor lesions, neck lymph node metastasis, local invasion of the tumor, extent of glandular lobectomy, and mutation of BRAF V600E significantly influenced the postoperative recurrence of thyroid cancer (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05). In contrast, age, BMI, tumor location, pathological stage, the presence of HT, and preoperative and postoperative serum levels of Tg, TSH, Tgab, and TPOab did not have a significant effect on postoperative recurrence (<italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05). Please refer to Table&#160;<xref rid="Tab2" ref-type="table">2</xref>.</p><p id="Par15">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Univariate Cox regression analysis of relapse correlation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variable</th><th align="left" colspan="1" rowspan="1">B</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1">Wald</th><th align="left" colspan="1" rowspan="1">
<italic toggle="yes">P</italic>
</th><th align="left" colspan="1" rowspan="1">HR</th><th align="left" colspan="1" rowspan="1">Lower limit</th><th align="left" colspan="1" rowspan="1">Upper limit</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Gender</td><td char="." align="char" colspan="1" rowspan="1">0.876</td><td char="." align="char" colspan="1" rowspan="1">0.303</td><td char="." align="char" colspan="1" rowspan="1">8.366</td><td char="." align="char" colspan="1" rowspan="1">0.004</td><td char="." align="char" colspan="1" rowspan="1">2.400</td><td char="." align="char" colspan="1" rowspan="1">1.326</td><td char="." align="char" colspan="1" rowspan="1">4.344</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Age of</p><p>first operation</p></td><td char="." align="char" colspan="1" rowspan="1">-0.019</td><td char="." align="char" colspan="1" rowspan="1">0.013</td><td char="." align="char" colspan="1" rowspan="1">1.998</td><td char="." align="char" colspan="1" rowspan="1">0.158</td><td char="." align="char" colspan="1" rowspan="1">0.982</td><td char="." align="char" colspan="1" rowspan="1">0.957</td><td char="." align="char" colspan="1" rowspan="1">1.007</td></tr><tr><td align="left" colspan="1" rowspan="1">BMI</td><td char="." align="char" colspan="1" rowspan="1">-0.001</td><td char="." align="char" colspan="1" rowspan="1">0.040</td><td char="." align="char" colspan="1" rowspan="1">0.000</td><td char="." align="char" colspan="1" rowspan="1">0.983</td><td char="." align="char" colspan="1" rowspan="1">0.999</td><td char="." align="char" colspan="1" rowspan="1">0.925</td><td char="." align="char" colspan="1" rowspan="1">1.080</td></tr><tr><td align="left" colspan="1" rowspan="1">Bilateral total thyroidectomy</td><td char="." align="char" colspan="1" rowspan="1">-0.957</td><td char="." align="char" colspan="1" rowspan="1">0.305</td><td char="." align="char" colspan="1" rowspan="1">9.821</td><td char="." align="char" colspan="1" rowspan="1">0.002</td><td char="." align="char" colspan="1" rowspan="1">0.384</td><td char="." align="char" colspan="1" rowspan="1">0.211</td><td char="." align="char" colspan="1" rowspan="1">0.699</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Subtotal</p><p>thyroidectomy</p></td><td char="." align="char" colspan="1" rowspan="1">-0.337</td><td char="." align="char" colspan="1" rowspan="1">0.617</td><td char="." align="char" colspan="1" rowspan="1">0.298</td><td char="." align="char" colspan="1" rowspan="1">0.585</td><td char="." align="char" colspan="1" rowspan="1">0.714</td><td char="." align="char" colspan="1" rowspan="1">0.213</td><td char="." align="char" colspan="1" rowspan="1">2.394</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Tumor</p><p>diameter</p></td><td char="." align="char" colspan="1" rowspan="1">0.668</td><td char="." align="char" colspan="1" rowspan="1">0.081</td><td char="." align="char" colspan="1" rowspan="1">67.863</td><td char="." align="char" colspan="1" rowspan="1">&lt;0.001</td><td char="." align="char" colspan="1" rowspan="1">1.950</td><td char="." align="char" colspan="1" rowspan="1">1.664</td><td char="." align="char" colspan="1" rowspan="1">2.286</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Number of tumor</p><p>lesions</p></td><td char="." align="char" colspan="1" rowspan="1">0.265</td><td char="." align="char" colspan="1" rowspan="1">0.090</td><td char="." align="char" colspan="1" rowspan="1">8.580</td><td char="." align="char" colspan="1" rowspan="1">0.003</td><td char="." align="char" colspan="1" rowspan="1">1.303</td><td char="." align="char" colspan="1" rowspan="1">1.092</td><td char="." align="char" colspan="1" rowspan="1">1.556</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Tumor</p><p>location</p></td><td char="." align="char" colspan="1" rowspan="1">0.458</td><td char="." align="char" colspan="1" rowspan="1">0.300</td><td char="." align="char" colspan="1" rowspan="1">2.326</td><td char="." align="char" colspan="1" rowspan="1">0.127</td><td char="." align="char" colspan="1" rowspan="1">1.581</td><td char="." align="char" colspan="1" rowspan="1">0.878</td><td char="." align="char" colspan="1" rowspan="1">2.848</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>TNM</p><p>stage</p></td><td char="." align="char" colspan="1" rowspan="1">0.893</td><td char="." align="char" colspan="1" rowspan="1">1.012</td><td char="." align="char" colspan="1" rowspan="1">0.779</td><td char="." align="char" colspan="1" rowspan="1">0.378</td><td char="." align="char" colspan="1" rowspan="1">2.443</td><td char="." align="char" colspan="1" rowspan="1">0.336</td><td char="." align="char" colspan="1" rowspan="1">17.767</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Central lymph</p><p>node metastasis</p></td><td char="." align="char" colspan="1" rowspan="1">1.558</td><td char="." align="char" colspan="1" rowspan="1">0.336</td><td char="." align="char" colspan="1" rowspan="1">21.473</td><td char="." align="char" colspan="1" rowspan="1">&lt;0.001</td><td char="." align="char" colspan="1" rowspan="1">4.747</td><td char="." align="char" colspan="1" rowspan="1">2.457</td><td char="." align="char" colspan="1" rowspan="1">9.174</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Lateral lymph</p><p>node metastasis</p></td><td char="." align="char" colspan="1" rowspan="1">2.086</td><td char="." align="char" colspan="1" rowspan="1">0.302</td><td char="." align="char" colspan="1" rowspan="1">47.871</td><td char="." align="char" colspan="1" rowspan="1">&lt;0.001</td><td char="." align="char" colspan="1" rowspan="1">8.055</td><td char="." align="char" colspan="1" rowspan="1">4.461</td><td char="." align="char" colspan="1" rowspan="1">14.545</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Local</p><p>invasion</p></td><td char="." align="char" colspan="1" rowspan="1">1.108</td><td char="." align="char" colspan="1" rowspan="1">0.358</td><td char="." align="char" colspan="1" rowspan="1">9.574</td><td char="." align="char" colspan="1" rowspan="1">0.002</td><td char="." align="char" colspan="1" rowspan="1">3.028</td><td char="." align="char" colspan="1" rowspan="1">1.501</td><td char="." align="char" colspan="1" rowspan="1">6.108</td></tr><tr><td align="left" colspan="1" rowspan="1">Combined with HT</td><td char="." align="char" colspan="1" rowspan="1">-0.311</td><td char="." align="char" colspan="1" rowspan="1">0.439</td><td char="." align="char" colspan="1" rowspan="1">0.504</td><td char="." align="char" colspan="1" rowspan="1">0.478</td><td char="." align="char" colspan="1" rowspan="1">0.733</td><td char="." align="char" colspan="1" rowspan="1">0.310</td><td char="." align="char" colspan="1" rowspan="1">1.730</td></tr><tr><td align="left" colspan="1" rowspan="1">Radioiodine therapy</td><td char="." align="char" colspan="1" rowspan="1">0.851</td><td char="." align="char" colspan="1" rowspan="1">0.300</td><td char="." align="char" colspan="1" rowspan="1">8.067</td><td char="." align="char" colspan="1" rowspan="1">0.005</td><td char="." align="char" colspan="1" rowspan="1">2.343</td><td char="." align="char" colspan="1" rowspan="1">1.302</td><td char="." align="char" colspan="1" rowspan="1">4.216</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>BRAF V600E</p><p>gene expression</p></td><td char="." align="char" colspan="1" rowspan="1">1.168</td><td char="." align="char" colspan="1" rowspan="1">0.411</td><td char="." align="char" colspan="1" rowspan="1">8.096</td><td char="." align="char" colspan="1" rowspan="1">0.004</td><td char="." align="char" colspan="1" rowspan="1">3.216</td><td char="." align="char" colspan="1" rowspan="1">1.438</td><td char="." align="char" colspan="1" rowspan="1">7.192</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Preoperative serum</p><p>TSH levels</p></td><td char="." align="char" colspan="1" rowspan="1">-0.035</td><td char="." align="char" colspan="1" rowspan="1">0.068</td><td char="." align="char" colspan="1" rowspan="1">0.269</td><td char="." align="char" colspan="1" rowspan="1">0.604</td><td char="." align="char" colspan="1" rowspan="1">0.966</td><td char="." align="char" colspan="1" rowspan="1">0.846</td><td char="." align="char" colspan="1" rowspan="1">1.102</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Preoperative serum</p><p>Tg levels</p></td><td char="." align="char" colspan="1" rowspan="1">0.003</td><td char="." align="char" colspan="1" rowspan="1">0.002</td><td char="." align="char" colspan="1" rowspan="1">3.116</td><td char="." align="char" colspan="1" rowspan="1">0.078</td><td char="." align="char" colspan="1" rowspan="1">1.003</td><td char="." align="char" colspan="1" rowspan="1">1.000</td><td char="." align="char" colspan="1" rowspan="1">1.006</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Preoperative serum</p><p>Tgab levels</p></td><td char="." align="char" colspan="1" rowspan="1">0.000</td><td char="." align="char" colspan="1" rowspan="1">0.000</td><td char="." align="char" colspan="1" rowspan="1">0.003</td><td char="." align="char" colspan="1" rowspan="1">0.957</td><td char="." align="char" colspan="1" rowspan="1">1.000</td><td char="." align="char" colspan="1" rowspan="1">0.999</td><td char="." align="char" colspan="1" rowspan="1">1.001</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Preoperative serum</p><p>TPOab levels</p></td><td char="." align="char" colspan="1" rowspan="1">-0.002</td><td char="." align="char" colspan="1" rowspan="1">0.002</td><td char="." align="char" colspan="1" rowspan="1">0.929</td><td char="." align="char" colspan="1" rowspan="1">0.335</td><td char="." align="char" colspan="1" rowspan="1">0.998</td><td char="." align="char" colspan="1" rowspan="1">0.994</td><td char="." align="char" colspan="1" rowspan="1">1.002</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Postoperative serum</p><p>TSH levels</p></td><td char="." align="char" colspan="1" rowspan="1">0.003</td><td char="." align="char" colspan="1" rowspan="1">0.012</td><td char="." align="char" colspan="1" rowspan="1">0.043</td><td char="." align="char" colspan="1" rowspan="1">0.836</td><td char="." align="char" colspan="1" rowspan="1">1.003</td><td char="." align="char" colspan="1" rowspan="1">0.979</td><td char="." align="char" colspan="1" rowspan="1">1.027</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Postoperative serum</p><p>Tg levels</p></td><td char="." align="char" colspan="1" rowspan="1">0.001</td><td char="." align="char" colspan="1" rowspan="1">0.004</td><td char="." align="char" colspan="1" rowspan="1">0.020</td><td char="." align="char" colspan="1" rowspan="1">0.888</td><td char="." align="char" colspan="1" rowspan="1">1.001</td><td char="." align="char" colspan="1" rowspan="1">0.993</td><td char="." align="char" colspan="1" rowspan="1">1.009</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Postoperative serum</p><p>Tgab levels</p></td><td char="." align="char" colspan="1" rowspan="1">0.000</td><td char="." align="char" colspan="1" rowspan="1">0.000</td><td char="." align="char" colspan="1" rowspan="1">0.021</td><td char="." align="char" colspan="1" rowspan="1">0.884</td><td char="." align="char" colspan="1" rowspan="1">1.000</td><td char="." align="char" colspan="1" rowspan="1">0.999</td><td char="." align="char" colspan="1" rowspan="1">1.001</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Postoperative serum</p><p>TPOab levels</p></td><td char="." align="char" colspan="1" rowspan="1">-0.003</td><td char="." align="char" colspan="1" rowspan="1">0.003</td><td char="." align="char" colspan="1" rowspan="1">0.853</td><td char="." align="char" colspan="1" rowspan="1">0.356</td><td char="." align="char" colspan="1" rowspan="1">0.997</td><td char="." align="char" colspan="1" rowspan="1">0.991</td><td char="." align="char" colspan="1" rowspan="1">1.003</td></tr></tbody></table><table-wrap-foot><p>*BMI: Body Mass Index. *HT: Hashimoto&#8217;s thyroiditis.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec6"><title>Multifactorial Cox regression analysis of postoperative recurrence in patients with DTC</title><p id="Par16">Please refer to Table&#160;<xref rid="Tab3" ref-type="table">3</xref>. The indicators suggest that significant factors influencing prognosis in the univariate analysis will be utilized as independent variables, while recurrence will serve as the dependent variable in the multivariate regression analysis. The results indicate that male gender, tumor diameter, the number of tumor lesions, preoperative lymph node metastasis, and BRAF V600E gene mutation are independent risk factors for the recurrence of DTC (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05). Conversely, bilateral total thyroidectomy is identified as an independent protective factor against the recurrence of DTC (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05). Recurrence curves are presented separately for each of the following variables: excision scope (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>), central lymph node metastasis (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>), lateral lymph node metastasis (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>), and BRAF V600E gene mutation (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>).</p><p id="Par17">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Cox regression analysis of multiple factors related to recurrence.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Variable</th><th align="left" colspan="7" rowspan="1">Cox regression model</th><th align="left" colspan="2" rowspan="1">Bootstrap</th></tr><tr><th align="left" colspan="1" rowspan="1">B</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1">Wald</th><th align="left" colspan="1" rowspan="1">P</th><th align="left" colspan="1" rowspan="1">HR</th><th align="left" colspan="1" rowspan="1">Lower limit</th><th align="left" colspan="1" rowspan="1">Upper limit</th><th align="left" colspan="1" rowspan="1">B</th><th align="left" colspan="1" rowspan="1">P</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Gender</td><td align="left" colspan="1" rowspan="1">0.644</td><td align="left" colspan="1" rowspan="1">0.322</td><td align="left" colspan="1" rowspan="1">4.005</td><td align="left" colspan="1" rowspan="1">0.045</td><td align="left" colspan="1" rowspan="1">1.903</td><td align="left" colspan="1" rowspan="1">1.013</td><td align="left" colspan="1" rowspan="1">3.574</td><td align="left" colspan="1" rowspan="1">-0.052</td><td align="left" colspan="1" rowspan="1">0.049</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Number of tumor</p><p>lesions</p></td><td align="left" colspan="1" rowspan="1">0.279</td><td align="left" colspan="1" rowspan="1">0.088</td><td align="left" colspan="1" rowspan="1">10.174</td><td align="left" colspan="1" rowspan="1">0.001</td><td align="left" colspan="1" rowspan="1">1.322</td><td align="left" colspan="1" rowspan="1">1.114</td><td align="left" colspan="1" rowspan="1">1.569</td><td align="left" colspan="1" rowspan="1">0.053</td><td align="left" colspan="1" rowspan="1">0.036</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Central lymph</p><p>node metastasis</p></td><td align="left" colspan="1" rowspan="1">1.241</td><td align="left" colspan="1" rowspan="1">0.446</td><td align="left" colspan="1" rowspan="1">7.740</td><td align="left" colspan="1" rowspan="1">0.005</td><td align="left" colspan="1" rowspan="1">3.458</td><td align="left" colspan="1" rowspan="1">1.443</td><td align="left" colspan="1" rowspan="1">8.290</td><td align="left" colspan="1" rowspan="1">0.054</td><td align="left" colspan="1" rowspan="1">0.004</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Lateral lymph</p><p>node metastasis</p></td><td align="left" colspan="1" rowspan="1">1.486</td><td align="left" colspan="1" rowspan="1">0.448</td><td align="left" colspan="1" rowspan="1">11.016</td><td align="left" colspan="1" rowspan="1">0.001</td><td align="left" colspan="1" rowspan="1">4.418</td><td align="left" colspan="1" rowspan="1">1.837</td><td align="left" colspan="1" rowspan="1">10.625</td><td align="left" colspan="1" rowspan="1">0.166</td><td align="left" colspan="1" rowspan="1">0.008</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>BRAF V600E</p><p>gene expression</p></td><td align="left" colspan="1" rowspan="1">1.008</td><td align="left" colspan="1" rowspan="1">0.432</td><td align="left" colspan="1" rowspan="1">5.431</td><td align="left" colspan="1" rowspan="1">0.020</td><td align="left" colspan="1" rowspan="1">2.739</td><td align="left" colspan="1" rowspan="1">1.174</td><td align="left" colspan="1" rowspan="1">6.393</td><td align="left" colspan="1" rowspan="1">0.091</td><td align="left" colspan="1" rowspan="1">0.020</td></tr><tr><td align="left" colspan="1" rowspan="1">Tumor diameter</td><td align="left" colspan="1" rowspan="1">0.583</td><td align="left" colspan="1" rowspan="1">0.122</td><td align="left" colspan="1" rowspan="1">22.977</td><td align="left" colspan="1" rowspan="1">&lt;0.001</td><td align="left" colspan="1" rowspan="1">1.791</td><td align="left" colspan="1" rowspan="1">1.411</td><td align="left" colspan="1" rowspan="1">2.273</td><td align="left" colspan="1" rowspan="1">0.045</td><td align="left" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Bilateral total</p><p>thyroidectomy</p></td><td align="left" colspan="1" rowspan="1">-2.435</td><td align="left" colspan="1" rowspan="1">0.431</td><td align="left" colspan="1" rowspan="1">31.856</td><td align="left" colspan="1" rowspan="1">&lt;0.001</td><td align="left" colspan="1" rowspan="1">0.088</td><td align="left" colspan="1" rowspan="1">0.038</td><td align="left" colspan="1" rowspan="1">0.204</td><td align="left" colspan="1" rowspan="1">-0.233</td><td align="left" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Subtotal</p><p>thyroidectomy</p></td><td align="left" colspan="1" rowspan="1">0.015</td><td align="left" colspan="1" rowspan="1">0.660</td><td align="left" colspan="1" rowspan="1">0.001</td><td align="left" colspan="1" rowspan="1">0.982</td><td align="left" colspan="1" rowspan="1">1.015</td><td align="left" colspan="1" rowspan="1">0.279</td><td align="left" colspan="1" rowspan="1">3.697</td><td align="left" colspan="1" rowspan="1">-0.743</td><td align="left" colspan="1" rowspan="1">0.986</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Local</p><p>invasion</p></td><td align="left" colspan="1" rowspan="1">0.669</td><td align="left" colspan="1" rowspan="1">0.439</td><td align="left" colspan="1" rowspan="1">2.327</td><td align="left" colspan="1" rowspan="1">0.127</td><td align="left" colspan="1" rowspan="1">1.952</td><td align="left" colspan="1" rowspan="1">0.826</td><td align="left" colspan="1" rowspan="1">4.613</td><td align="left" colspan="1" rowspan="1">-0.034</td><td align="left" colspan="1" rowspan="1">0.206</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Radioiodine</p><p>therapy</p></td><td align="left" colspan="1" rowspan="1">-0.344</td><td align="left" colspan="1" rowspan="1">0.569</td><td align="left" colspan="1" rowspan="1">0.365</td><td align="left" colspan="1" rowspan="1">0.546</td><td align="left" colspan="1" rowspan="1">0.709</td><td align="left" colspan="1" rowspan="1">0.232</td><td align="left" colspan="1" rowspan="1">2.163</td><td align="left" colspan="1" rowspan="1">0.062</td><td align="left" colspan="1" rowspan="1">0.638</td></tr></tbody></table></table-wrap>
</p><p id="Par18">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Recurrence risk function with respect to excision scope.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1507" position="float" orientation="portrait" xlink:href="41598_2025_18385_Fig1_HTML.jpg"/></fig>
</p><p id="Par19">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Recurrence risk function with or without central lymph node metastasis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1517" position="float" orientation="portrait" xlink:href="41598_2025_18385_Fig2_HTML.jpg"/></fig>
</p><p id="Par20">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Recurrence risk function with or without lateral lymph node metastasis.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1527" position="float" orientation="portrait" xlink:href="41598_2025_18385_Fig3_HTML.jpg"/></fig>
</p><p id="Par21">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Recurrence risk function with or without BRAF V600E Gene Expression.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1537" position="float" orientation="portrait" xlink:href="41598_2025_18385_Fig4_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec7"><title>Discussion</title><sec id="Sec8"><title>The impact of gender on prognosis</title><p id="Par22">Studies have shown that the recurrence rate of thyroid cancer after surgery is higher in males than in females<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR9">9</xref></sup>. However, one study indicated no difference in prognosis between the two genders<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. Our data demonstrate that male patients have a worse prognosis than female patients, and gender is an independent prognostic factor. A multicenter retrospective study also confirmed that males are a significant independent risk factor for specific mortality in patients with DTC associated with the BRAF V600E mutation<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>.</p></sec><sec id="Sec9"><title>The impact of tumor size and pathological stage on prognosis</title><p id="Par23">This study demonstrates that tumor diameter is an independent risk factor for the recurrence of DTC (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05). Recent research has also confirmed that tumor size serves as an independent predictor of survival without recurrence in DTC patients<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. However, the specific survival rate for T3b stage DTC patients with a tumor size of &#8804;&#8201;2&#160;cm is not statistically different from that of T1 stage patients<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. Additionally, this study indicates that there is no statistically significant difference in pathological staging between the recurrence group and the non-recurrence group.This may be due to the fact that in patients under the age of 55, regardless of tumor size or the presence of lymph node metastasis in the neck, they are classified as stage I as long as there is no distant metastasis. However, this classification does not accurately represent the quantitative relationship between pathological staging and prognosis. Furthermore, it is possible that the generally favorable prognosis of DTC leads to improved outcomes for patients across all stages, from stage I to stage IV, following surgical treatment.</p></sec><sec id="Sec10"><title>The impact of tumor multifocality, local invasion, and neck lymph node metastasis on prognosis</title><p id="Par24">Patients with multifocal and locally invasive DTC have a higher risk of central and lateral neck lymph node metastasis<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>. Consistent with relevant studies<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>, this research suggests that preoperative lymph node metastasis and the presence of multiple lesions are independent risk factors for the recurrence of DTC (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05), which may result in the existence of additional hidden lesions in the body. Although the lesions and lymph nodes identified prior to surgery may be completely excised, it remains challenging to entirely eliminate hidden lesions, potentially leading to an increased risk of postoperative recurrence. In this study, local tumor invasion is identified as a risk factor influencing the recurrence of thyroid cancer after surgery; however, it is not considered an independent risk factor.</p></sec><sec id="Sec11"><title>The impact of thyroidectomy extent on prognosis</title><p id="Par25">The extent of initial surgery for thyroid cancer has long been a subject of debate among experts. The latest guidelines in China recommend that patients with tumors larger than 4&#160;cm in diameter, tumors larger than 1&#160;cm located in the isthmus, positive surgical margins, visible extrathyroidal invasion, vascular invasion, bilateral multifocal lesions, clinical lymph node metastasis (number of nodes&#8201;&#8805;&#8201;5 or diameter&#8201;&#8805;&#8201;3&#160;cm) or distant metastasis should undergo total or near-total thyroidectomy. The American Thyroid Association (ATA) recommends that patients with tumors larger than 4&#160;cm, those exhibiting obvious extrathyroidal invasion, or those with confirmed lymph node metastasis should undergo total or near-total thyroidectomy<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. The extent of resection of the primary tumor significantly impacts the recurrence of DTC. In this study, bilateral thyroid lobe resection was identified as an independent protective factor against the recurrence of DTC (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05). A retrospective analysis of Korean patients with DTC indicated that total thyroidectomy did not provide a survival advantage over lobectomy, except in specific high-risk groups<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>. Surgeons must balance the risk of postoperative complications, such as hypoparathyroidism and recurrent laryngeal nerve injury<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>, while considering factors such as tumor size and regional lymph node metastasis, etc. to tailor an individualized surgical strategy that optimizes postoperative quality of life and minimizes the risk of recurrence.</p></sec><sec id="Sec12"><title>The impact of BRAF V600E gene mutation on prognosis</title><p id="Par26">V600E mutation is the most frequently observed alteration in the BRAF oncogene, exhibiting a high mutation rate<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. Although the ATA guidelines indicate that the specificity and sensitivity of the BRAF V600E gene mutation in predicting the risk of recurrence in DTC remain contentious<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>, study have demonstrated that the BRAF V600E mutation is positively correlated with aggressive factors such as lymph node metastasis and lymphatic vessel invasion in DTC<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. Furthermore, several studies have confirmed that the BRAF V600E gene mutation is closely associated with an increased risk of recurrence<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup>. This study establishes that the BRAF V600E gene mutation is an independent risk factor for recurrence in DTC (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05). For patients with DTC harboring the BRAF V600E gene mutation, a more aggressive surgical approach is recommended, followed by postoperative evaluation for 131I clearance therapy, and follow-up should be conducted with greater rigor.</p></sec><sec id="Sec13"><title>The impact of HT on prognosis</title><p id="Par27">HT is negatively correlated with the aggressive pathological features of DTC; however, it does not significantly impact overall survival or disease-free survival in patients following surgery<sup><xref ref-type="bibr" rid="CR23">23</xref>,<xref ref-type="bibr" rid="CR24">24</xref></sup>. Additionally, it is rarely identified as an independent protective factor in multivariate analyses<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. In this study, there was no statistically significant difference in the recurrence rates between patients with HT and those without it in both the recurrence and non-recurrence groups (both <italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05). However, a limitation of this study is that it did not analyze patients with HT who developed DTC, focusing only on cases where both conditions coexisted. Furthermore, the prior diagnosis and treatment history of HT in the patients were not documented.</p></sec><sec id="Sec14"><title>The impact of laboratory test results on prognosis</title><p id="Par28">Luca et al. established a decision tree model to predict the recurrence of DTC based on postoperative serum Tg levels<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Meanwhile, Martin et al. indicated through retrospective analysis that preoperative Tg can guide the initial treatment and follow-up management of DTC<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. In this study, single-factor Cox regression analysis demonstrated that preoperative and postoperative serum Tg, TSH, Tgab, and TPOab had no significant impact on postoperative recurrence (<italic toggle="yes">P</italic>&#8201;&gt;&#8201;0.05).</p><p id="Par29">While postoperative serum Tg showed statistical significance in our univariate chi-square test (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05), its utility as a standalone marker for recurrence is limited in cohorts with mixed surgical approaches. In patients with residual thyroid tissue (e.g., after lobectomy), elevated Tg may reflect physiological remnant activity rather than recurrence. Therefore, Tg trends should be interpreted contextually: in total thyroidectomy patients, a Tg level greater than 1 ng/mL suggests an increased risk of recurrence; in lobectomy patients, a Tg level exceeding 10 ng/mL or rising trends warrant further investigation.</p><p id="Par30">Preoperative serum Tg, TSH, Tgab, and TPOab can be combined with relevant imaging examinations to assist in the diagnosis of thyroid tumors. Additionally, postoperative serum levels can aid in assessing prognosis, with serum Tg being a crucial indicator for monitoring residual thyroid tissue after total thyroidectomy or radioactive iodine (<sup>131</sup>I) therapy for DTC. Although HT does not worsen the prognosis of DTC<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>, it is still recommended to monitor TPOab levels both preoperatively and postoperatively to mitigate the uncertain effects of HT.</p></sec><sec id="Sec15"><title>Clinical application of the nomogram</title><p id="Par31">The nomogram developed from our multivariate Cox regression model serves as a practical tool for assessing individualized recurrence risk in DTC patients. Clinicians can determine a patient&#8217;s probability of recurrence by summing the points assigned to key predictors. Please refer to Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>.</p><p id="Par32">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Nomogram for recurrence risk in DTC patients. (To use it, locate each predictor variable, draw a vertical line to the &#8220;Points&#8221; axis to assign points, sum all points, and project the total to the &#8220;Linear Predictor&#8221; axes. Higher total points indicate increased recurrence risk.)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e1699" position="float" orientation="portrait" xlink:href="41598_2025_18385_Fig5_HTML.jpg"/></fig>
</p><p id="Par33">Clinical Utility:</p><p id="Par34">
<list list-type="bullet"><list-item><p id="Par35">Risk Stratification: This process identifies high-risk patients (e.g., those with total points exceeding 100) who require intensive surveillance. As mentioned earlier, frequent follow-ups were conducted.</p></list-item><list-item><p id="Par36">Treatment Guidance: Provides support for decisions regarding bilateral resection or adjuvant RAI therapy in high-risk cases. (Current guidelines<sup><xref ref-type="bibr" rid="CR7">7</xref></sup> strongly recommend adjuvant RAI for high-risk DTC, such as cases with gross extrathyroidal extension or lateral N1b metastasis.)</p></list-item><list-item><p id="Par37">Patient Counseling: Effectively conveys personalized recurrence risk through visual communication.</p></list-item></list>
</p></sec></sec><sec id="Sec16"><title>Conclusions</title><p id="Par38">Combined with our data, the developed nomogram provides a clinically actionable tool for recurrence risk quantification. We recommend that high-risk patients with differentiated thyroid cancer&#8212;such as those with bilateral lymph node metastasis identified through imaging examinations, BRAF V600E gene mutations, and those with large tumor volumes and multifocal lesions revealed by rapid intraoperative pathological examination&#8212;be considered for bilateral thyroid lobectomy. The nomogram objectively identifies these high-risk profiles and quantifies how surgical choices influence recurrence probability. For the management of cervical lymph nodes, therapeutic cervical lymph node dissection is advised. A comprehensive perioperative evaluation should be conducted, and preoperative communication with patients must be prioritized.</p><p id="Par39">There are still some limitations in this experiment. First, the follow-up period in this study was limited to 36 to 60 months. Although this duration is sufficient to capture early recurrences, it may not be adequate for identifying late recurrences, which can occur many years after initial treatment. Longer follow-up periods are necessary to fully understand the long-term recurrence patterns and outcomes in DTC patients. Second, the study did not document the specific locations of tumor occurrences within the thyroid gland. The precise location of the tumor (e.g., upper pole, lower pole, isthmus) may influence the risk of recurrence and should be considered in future studies. Despite these limitations, the findings of this study contribute to the growing body of evidence regarding the risk factors for postoperative recurrence of DTC. Addressing these limitations in future research will provide a more comprehensive understanding of DTC recurrence and help refine clinical guidelines for the management and follow-up of DTC patients.</p></sec><sec id="Sec17"><title>Methods</title><sec id="Sec18"><title>Selection and characteristics of the patients</title><p id="Par40">Based on the established inclusion and exclusion criteria, a total of 1,118 patients diagnosed with DTC after undergoing thyroid cancer surgery between June 2019 and June 2021 were included in this study with a follow-up period of 36 to 60 months (i.e., 3 to 5 years). **Inclusion criteria: ** 1)Patients with a postoperative pathological diagnosis of differentiated thyroid carcinoma (DTC), including papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC); 2) Patients with complete clinical data who consented to participate in follow-up visits, either by telephone or in-person outpatient visits. **Exclusion criteria: ** (1) Pathological diagnosis of undifferentiated cancer, medullary cancer, or benign tumors; (2) Patients with concomitant malignant tumors at other sites or distant metastases to the liver, lungs, etc.; (3) Patients with incomplete clinical data, those who refused follow-up visits, or those lost to follow-up (i.e., failed to attend outpatient reviews or provided incorrect contact information).</p></sec><sec id="Sec19"><title>Study groups and data collection</title><p id="Par41">We conducted telephone follow-ups, outpatient follow-ups, and other methods to monitor selected patients. If the routine pathological examination results from the second surgery indicate recurrence of thyroid bed or residual thyroid tissue, central zone lymph node metastasis, or lateral neck lymph node metastasis, it is classified as recurrence. We then document the recurrence status of the patients. Patients are categorized into a recurrence group and a non-recurrence group based on the presence of DTC in the pathology results. Data from both groups are collected, including:</p><p id="Par42">
<list list-type="bullet"><list-item><p id="Par43">Basic information includes age, gender, and Body Mass Index (BMI).</p></list-item><list-item><p id="Par44">Pathology-related information includes the TNM stage (refer to the 2015 ATA guidelines for the diagnosis and treatment of thyroid nodules and differentiated thyroid cancers<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>, the size of the primary tumor (measured by its maximum diameter), the presence of single or multiple tumors, local invasion(the tumor clearly invades surrounding structures and organs, including the recurrent laryngeal nerve, trachea, esophagus, larynx, and the outer banded muscles, such as the hyoid, sternohyoid, sternothyroid, and thyrohyoid muscles), the presence of neck lymph node metastasis, co-occurrence with Hashimoto&#8217;s thyroiditis (HT), and the mutation of the BRAF V600E gene (the status of BRAF V600E was clinically assessed in tumor tissues using a PCR-based detection method conducted by the CAP-certified laboratory at this center).</p></list-item><list-item><p id="Par45">Treatment-related factors include the extent of surgical resection (bilateral total thyroidectomy, subtotal thyroidectomy, or unilateral lobectomy), as well as preoperative and postoperative serum levels of thyroid-stimulating hormone (TSH), thyroglobulin (Tg), thyroglobulin antibody (Tgab), and thyroid peroxidase antibody (TPOab).</p></list-item></list>
</p><p id="Par46">Thyroid hormone supplementation is initiated on the second day following a total thyroidectomy. The dosage is adjusted based on laboratory results obtained one month post-surgery. In the case of unilateral thyroid lobectomy, the necessity for thyroid hormone supplementation and the appropriate dosage are determined based on laboratory results one month after the surgery. Patients with DTC who are at medium to high risk of recurrence receive radioactive iodine (<sup>131</sup>I) therapy as an adjuvant treatment. Thyroid hormone supplementation begins 24 to 72&#160;h after RAI treatment, with dosage adjustments made after a follow-up period of 4 to 6 weeks.Medication is administered according to individual patient conditions to maintain normal thyroid function.</p></sec><sec id="Sec20"><title>Statistical method</title><p id="Par47">Using SPSS 26.0 software for data analysis, count data is represented as n (%), and comparisons between two groups are conducted using the <italic toggle="yes">&#967;</italic>&#178; test. Non-normally distributed quantitative data is expressed as <italic toggle="yes">M</italic>(<italic toggle="yes">P</italic> 25, <italic toggle="yes">P</italic> 75), and comparisons between two groups are performed using the Mann-Whitney U test. After conducting univariate Cox regression analysis on correlated data, multivariable Cox regression analysis is employed to assess the risk factors influencing recurrence. A p-value of less than 0.05 is considered statistically significant.Please refer to Table&#160;<xref rid="Tab4" ref-type="table">4</xref> for detailed assignments.</p><p id="Par48">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Assignment table.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variable</th><th align="left" colspan="1" rowspan="1">Assignment</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">group</td><td align="left" colspan="1" rowspan="1">No recurrence&#8201;=&#8201;0; recrudescence&#8201;=&#8201;1</td></tr><tr><td align="left" colspan="1" rowspan="1">Gender</td><td align="left" colspan="1" rowspan="1">Female&#8201;=&#8201;0; Male&#8201;=&#8201;1</td></tr><tr><td align="left" colspan="1" rowspan="1">Excision range</td><td align="left" colspan="1" rowspan="1"><p>Unilateral lobectomy =&#8201;0;</p><p>Bilateral total thyroidectomy =&#8201;1;</p><p>Subtotal thyroidectomy=&#8201;2</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Tumor location</td><td align="left" colspan="1" rowspan="1">Unilateral thyroid&#8201;=&#8201;0;Bilateral thyroid&#8201;=&#8201;1</td></tr><tr><td align="left" colspan="1" rowspan="1">TNM stage</td><td align="left" colspan="1" rowspan="1">I, II = 0; III, IV = 1</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Central lymph node</p><p>metastasis</p></td><td align="left" colspan="1" rowspan="1">No&#8201;=&#8201;1; Yes&#8201;=&#8201;1</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>Lateral lymph node</p><p>metastasis</p></td><td align="left" colspan="1" rowspan="1">No&#8201;=&#8201;0; Yes&#8201;=&#8201;1</td></tr><tr><td align="left" colspan="1" rowspan="1">Local invasion</td><td align="left" colspan="1" rowspan="1">No&#8201;=&#8201;0; Yes&#8201;=&#8201;1</td></tr><tr><td align="left" colspan="1" rowspan="1">Combined with HT</td><td align="left" colspan="1" rowspan="1">No&#8201;=&#8201;0; Yes&#8201;=&#8201;1</td></tr><tr><td align="left" colspan="1" rowspan="1">Radioiodine therapy</td><td align="left" colspan="1" rowspan="1">No&#8201;=&#8201;0; Yes&#8201;=&#8201;1</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>BRAF V600E gene</p><p>expression</p></td><td align="left" colspan="1" rowspan="1">No&#8201;=&#8201;0; Yes&#8201;=&#8201;1</td></tr></tbody></table><table-wrap-foot><p>*HT: Hashimoto&#8217;s thyroiditis.</p></table-wrap-foot></table-wrap>
</p><p id="Par49">The bootstrap method was employed to independently sample 1,000 times for verification. The deviation of the regression equation B was small, and the variables in the model remained significant. Consequently, the model based on this real-world data was more robust.</p></sec><sec id="Sec21"><title>A statement about ethics</title><p id="Par50">This retrospective study was conducted in accordance with the Declaration of Helsinki and received approval from the Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University (Approval Number: K202412-52).</p><p id="Par51">Due to the retrospective nature of the study, which involved analyzing anonymized existing clinical data without any additional intervention or risk to participants, the Ethics Committee waived the requirement for obtaining individual informed consent. Patient confidentiality was strictly maintained throughout the research process; all personal identifiers were removed or anonymized prior to data analysis.</p></sec></sec><sec id="Sec22" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_18385_MOESM1_ESM.xlsx" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author contributions</title><p>S.H.,H.G.-W, W.Y.: Conceptualization and design of study.S.H.and H.G.-W.:Methodology.Y.Q.-Y.,D.A.:Software.W.Y.:Validation. S.H.:Formal analysis. Y.Q.-Y.,D.A.:Investigation.S.H.,Y.Q.-Y.:Data curation. S.H.:Writing-original draft.H.G.-W.:Writing-review &amp; editing.W.Y.:Project administration. All authors reviewed the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This research was funded by the Health Commission of the Xinjiang Uygur Autonomous Region of China, under grant reference number TSYC202401A062.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The authors declare that the primary data generated or analysed during this study are available within the article and its supplementary information files. Additional data can be obtained from the corresponding author upon reasonable request.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par52">The authors declare no competing interests.</p></notes><notes id="FPar2"><title>Informed consent</title><p id="Par53">This study was approved by the Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University (Approval Number: K202412-52), and informed consent was waived due to the retrospective nature of the study by the Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University which utilized anonymized clinical data without additional risk to participants.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">International Agency for Research on Cancer WHO. GLOBOCAN. (2022, accessed 10 Nov 2024). <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://gco.iarc.fr/today/en2024">https://gco.iarc.fr/today/en2024</ext-link>.</mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bray</surname><given-names>F</given-names></name><etal/></person-group><article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA cancer J clin. 2020;70(4):313. Doi: 10.3322/caac.21609]</article-title><source>CA Cancer J. Clin.</source><year>2018</year><volume>68</volume><issue>6</issue><fpage>394</fpage><lpage>424</lpage><pub-id pub-id-type="doi">10.3322/caac.21492</pub-id><pub-id pub-id-type="pmid">30207593</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA cancer J. Clin. 2020;70(4):313. Doi: 10.3322/caac.21609]. <italic toggle="yes">CA Cancer J. Clin.</italic><bold>68</bold> (6), 394&#8211;424. 10.3322/caac.21492 (2018).<pub-id pub-id-type="pmid">30207593</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3322/caac.21492</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boucai</surname><given-names>L</given-names></name><name name-style="western"><surname>Zafereo</surname><given-names>M</given-names></name><name name-style="western"><surname>Cabanillas</surname><given-names>ME</given-names></name><name name-style="western"><surname>Thyroid Cancer</surname></name></person-group><source>Rev. JAMA</source><year>2024</year><volume>331</volume><issue>5</issue><fpage>425</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1001/jama.2023.26348</pub-id><pub-id pub-id-type="pmid">38319329</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Boucai, L., Zafereo, M. &amp; Cabanillas, M. E. Thyroid cancer. <italic toggle="yes">Rev. JAMA</italic><bold>331</bold> (5), 425&#8211;435. doi:10.1001/jama.2023.26348 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2023.26348</pub-id><pub-id pub-id-type="pmid">38319329</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurtom</surname><given-names>S</given-names></name><etal/></person-group><article-title>Tumor size and molecular risk group are associated with differentiated thyroid cancer recurrence</article-title><source>Surgery</source><year>2025</year><volume>177</volume><fpage>108838</fpage><pub-id pub-id-type="doi">10.1016/j.surg.2024.06.066</pub-id><pub-id pub-id-type="pmid">39384477</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Kurtom, S. et al. Tumor size and molecular risk group are associated with differentiated thyroid cancer recurrence. <italic toggle="yes">Surgery</italic><bold>177</bold>, 108838. 10.1016/j.surg.2024.06.066 (2025).<pub-id pub-id-type="pmid">39384477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.surg.2024.06.066</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Firat Atay</surname><given-names>F</given-names></name><etal/></person-group><article-title>A hybrid machine learning model combining association rule mining and classification algorithms to predict differentiated thyroid cancer recurrence</article-title><source>Front. Med. (Lausanne)</source><year>2024</year><volume>11</volume><fpage>1461372</fpage><pub-id pub-id-type="doi">10.3389/fmed.2024.146137</pub-id><pub-id pub-id-type="pmid">39430590</pub-id><pub-id pub-id-type="pmcid">PMC11486678</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Firat Atay, F. et al. A hybrid machine learning model combining association rule mining and classification algorithms to predict differentiated thyroid cancer recurrence. <italic toggle="yes">Front. Med. (Lausanne)</italic>. <bold>11</bold>, 1461372. 10.3389/fmed.2024.146137 (2024).<pub-id pub-id-type="pmid">39430590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmed.2024.1461372</pub-id><pub-id pub-id-type="pmcid">PMC11486678</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yan</surname><given-names>D</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S</given-names></name></person-group><article-title>The U-shaped association between age at diagnosis and recurrence in patients with papillary thyroid carcinoma: a retrospective single-institution cohort study</article-title><source>Eur. J. Surg. Oncol.</source><year>2024</year><volume>50</volume><issue>11</issue><fpage>108626</fpage><pub-id pub-id-type="doi">10.1016/j.ejso.2024.108626</pub-id><pub-id pub-id-type="pmid">39213698</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Huang, H., Liu, Y., Yan, D., Liu, W. &amp; Liu, S. The U-shaped association between age at diagnosis and recurrence in patients with papillary thyroid carcinoma: a retrospective single-institution cohort study. <italic toggle="yes">Eur. J. Surg. Oncol.</italic><bold>50</bold> (11), 108626. 10.1016/j.ejso.2024.108626 (2024).<pub-id pub-id-type="pmid">39213698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejso.2024.108626</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haugen</surname><given-names>BR</given-names></name><etal/></person-group><article-title>2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer</article-title><source>Thyroid</source><year>2016</year><volume>26</volume><issue>1</issue><fpage>1</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1089/thy.2015.0020</pub-id><pub-id pub-id-type="pmid">26462967</pub-id><pub-id pub-id-type="pmcid">PMC4739132</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Haugen, B. R. et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. <italic toggle="yes">Thyroid</italic><bold>26</bold> (1), 1&#8211;133. 10.1089/thy.2015.0020 (2016).<pub-id pub-id-type="pmid">26462967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/thy.2015.0020</pub-id><pub-id pub-id-type="pmcid">PMC4739132</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>X</given-names></name><name name-style="western"><surname>Wu</surname><given-names>ACYZYJBZJ</given-names></name></person-group><article-title>Analysis of risk factors for postoperative recurrence of thyroid cancer</article-title><source>J. BUON</source><year>2019</year><volume>24</volume><issue>2</issue><fpage>813</fpage><lpage>818</lpage><pub-id pub-id-type="pmid">31128040</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Luo, X. &amp; Wu, A. C. Y. Z. Y. J. B. Z. J. Analysis of risk factors for postoperative recurrence of thyroid cancer. <italic toggle="yes">J. BUON</italic>. <bold>24</bold> (2), 813&#8211;818 (2019).<pub-id pub-id-type="pmid">31128040</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yi</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Upregulation of the ESR1 gene and ESR ratio (ESR1/ESR2) is associated with a worse prognosis in papillary thyroid carcinoma: the impact of the Estrogen receptor &#945;/&#946; expression on clinical outcomes in papillary thyroid carcinoma patients</article-title><source>Ann. Surg. Oncol.</source><year>2017</year><volume>24</volume><issue>12</issue><fpage>3754</fpage><lpage>3762</lpage><pub-id pub-id-type="doi">10.1245/s10434-017-5780-z</pub-id><pub-id pub-id-type="pmid">28124274</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Yi, J. W. et al. Upregulation of the ESR1 gene and ESR ratio (ESR1/ESR2) is associated with a worse prognosis in papillary thyroid carcinoma: the impact of the Estrogen receptor &#945;/&#946; expression on clinical outcomes in papillary thyroid carcinoma patients. <italic toggle="yes">Ann. Surg. Oncol.</italic><bold>24</bold> (12), 3754&#8211;3762. 10.1245/s10434-017-5780-z (2017).<pub-id pub-id-type="pmid">28124274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1245/s10434-017-5780-z</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Konturek</surname><given-names>A</given-names></name><name name-style="western"><surname>Barczy&#324;ski</surname><given-names>M</given-names></name><name name-style="western"><surname>Nowak</surname><given-names>W</given-names></name><name name-style="western"><surname>Richter</surname><given-names>P</given-names></name></person-group><article-title>Prognostic factors in differentiated thyroid cancer&#8211;a 20-year surgical outcome study</article-title><source>Langenbecks Arch. Surg.</source><year>2012</year><volume>397</volume><issue>5</issue><fpage>809</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1007/s00423-011-0899-z</pub-id><pub-id pub-id-type="pmid">22350610</pub-id><pub-id pub-id-type="pmcid">PMC3349847</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Konturek, A., Barczy&#324;ski, M., Nowak, W. &amp; Richter, P. Prognostic factors in differentiated thyroid cancer&#8211;a 20-year surgical outcome study. <italic toggle="yes">Langenbecks Arch. Surg.</italic><bold>397</bold> (5), 809&#8211;815. 10.1007/s00423-011-0899-z (2012).<pub-id pub-id-type="pmid">22350610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00423-011-0899-z</pub-id><pub-id pub-id-type="pmcid">PMC3349847</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><etal/></person-group><article-title>BRAF V600E confers male sex disease-specific mortality risk in patients with papillary thyroid cancer</article-title><source>J. Clin. Oncol.</source><year>2018</year><volume>36</volume><issue>27</issue><fpage>2787</fpage><lpage>2795</lpage><pub-id pub-id-type="doi">10.1200/JCO.2018.78.5097</pub-id><pub-id pub-id-type="pmid">30070937</pub-id><pub-id pub-id-type="pmcid">PMC6145834</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Wang, F. et al. BRAF V600E confers male sex disease-specific mortality risk in patients with papillary thyroid cancer. <italic toggle="yes">J. Clin. Oncol.</italic><bold>36</bold> (27), 2787&#8211;2795. 10.1200/JCO.2018.78.5097 (2018).<pub-id pub-id-type="pmid">30070937</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1200/JCO.2018.78.5097</pub-id><pub-id pub-id-type="pmcid">PMC6145834</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Parvathareddy, S. K. et al. The prognostic impact of tumor size and BRAF mutational status in middle Eastern differentiated thyroid cancer. <italic toggle="yes">J. Clin. Endocrinol. Metab.</italic><bold>18</bold>, 785. 10.1210/clinem/dgae740 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgae740</pub-id><pub-id pub-id-type="pmcid">PMC12086394</pub-id><pub-id pub-id-type="pmid">39422185</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>J</given-names></name><name name-style="western"><surname>An</surname><given-names>S</given-names></name><name name-style="western"><surname>Bae</surname><given-names>JS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JS</given-names></name></person-group><article-title>Impact of tumor size on prognosis in differentiated thyroid cancer with gross extrathyroidal extension to strap muscles: redefining T3b</article-title><source>Cancers (Basel)</source><year>2024</year><volume>16</volume><issue>14</issue><fpage>2577</fpage><pub-id pub-id-type="doi">10.3390/cancers16142577</pub-id><pub-id pub-id-type="pmid">39061216</pub-id><pub-id pub-id-type="pmcid">PMC11274482</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Park, J., An, S., Bae, J. S., Kim, K. &amp; Kim, J. S. Impact of tumor size on prognosis in differentiated thyroid cancer with gross extrathyroidal extension to strap muscles: redefining T3b. <italic toggle="yes">Cancers (Basel)</italic>. <bold>16</bold> (14), 2577. 10.3390/cancers16142577 (2024).<pub-id pub-id-type="pmid">39061216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/cancers16142577</pub-id><pub-id pub-id-type="pmcid">PMC11274482</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Liang, Z. et al. Ultrasound and clinical factors predicting central lymph node metastases in patients with unilateral multifocal papillary thyroid carcinoma. <italic toggle="yes">Asia Pac. J. Clin. Oncol.</italic><bold>24</bold>, 896. 10.1111/ajco.14070 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ajco.14070</pub-id><pub-id pub-id-type="pmid">38659209</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>W</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Analysis of the clonal origin and differences in the biological behavior of multifocal papillary thyroid carcinoma</article-title><source>Oncol. Lett.</source><year>2024</year><volume>28</volume><issue>5</issue><fpage>544</fpage><pub-id pub-id-type="doi">10.3892/ol.2024.14677</pub-id><pub-id pub-id-type="pmid">39310023</pub-id><pub-id pub-id-type="pmcid">PMC11413729</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Sun, W., Hu, Q., Liu, Z., Zhang, Q. &amp; Wang, J. Analysis of the clonal origin and differences in the biological behavior of multifocal papillary thyroid carcinoma. <italic toggle="yes">Oncol. Lett.</italic><bold>28</bold> (5), 544. 10.3892/ol.2024.14677 (2024).<pub-id pub-id-type="pmid">39310023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ol.2024.14677</pub-id><pub-id pub-id-type="pmcid">PMC11413729</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Liu, C. et al. Nomograms to predict occult contralateral central lymph node metastases in unilateral papillary thyroid carcinoma with ipsilateral clinical lymph node metastasis. <italic toggle="yes">Oral Oncol.</italic><bold>14</bold>, 263. 10.1016/j.oraloncology.2024.107051 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.oraloncology.2024.107051</pub-id><pub-id pub-id-type="pmid">39406011</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>HS</given-names></name><etal/></person-group><article-title>Total thyroidectomy&#8217;s association with survival in papillary thyroid cancers and the high proportion of total thyroidectomy in low-risk patients: analysis of Korean nationwide data</article-title><source>Surgery</source><year>2019</year><volume>165</volume><issue>3</issue><fpage>629</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.1016/j.surg.2018.08.030</pub-id><pub-id pub-id-type="pmid">30342774</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Zhang, H. S. et al. Total thyroidectomy&#8217;s association with survival in papillary thyroid cancers and the high proportion of total thyroidectomy in low-risk patients: analysis of Korean nationwide data. <italic toggle="yes">Surgery</italic><bold>165</bold> (3), 629&#8211;636. 10.1016/j.surg.2018.08.030 (2019).<pub-id pub-id-type="pmid">30342774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.surg.2018.08.030</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lukinovi&#263;</surname><given-names>J</given-names></name><name name-style="western"><surname>Bili&#263;</surname><given-names>M</given-names></name></person-group><article-title>Overview of thyroid surgery complications</article-title><source>Acta Clin. Croat</source><year>2020</year><volume>59</volume><issue>Suppl 1</issue><fpage>81</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.20471/acc.2020.59.s1.10</pub-id><pub-id pub-id-type="pmid">34219888</pub-id><pub-id pub-id-type="pmcid">PMC8212606</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Lukinovi&#263;, J. &amp; Bili&#263;, M. Overview of thyroid surgery complications. <italic toggle="yes">Acta Clin. Croat</italic>. <bold>59</bold> (Suppl 1), 81&#8211;86. 10.20471/acc.2020.59.s1.10 (2020).<pub-id pub-id-type="pmid">34219888</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.20471/acc.2020.59.s1.10</pub-id><pub-id pub-id-type="pmcid">PMC8212606</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Zhou, S. L. et al. Predicting factors of central lymph node metastasis and BRAFV600E mutation in Chinese population with papillary thyroid carcinoma. <italic toggle="yes">World J. Surg. Oncol.</italic><bold>19</bold> (1), 211. 10.1186/s12957-021-02326-y (2021).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12957-021-02326-y</pub-id><pub-id pub-id-type="pmcid">PMC8278623</pub-id><pub-id pub-id-type="pmid">34256769</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Ye&#351;ilo&#287;lu, A. A., U&#287;uz, A. H., Erdo&#287;an, K. E. &amp; Sakman, G. Papillary microcarcinoma of the thyroid gland: evaluation of TERT and BRAFV-600E expression and their relationship with clinicopathological findings. <italic toggle="yes">Ann. Diagn. Pathol.</italic><bold>19</bold>, 256. 10.1016/j.anndiagpath.2024.152369 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.anndiagpath.2024.152369</pub-id><pub-id pub-id-type="pmid">39178758</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Cong, R., Ouyang, H., Zhou, D., Li, X. &amp; Xia, F. BRAF V600E mutation in thyroid carcinoma: a large-scale study in Han Chinese population. <italic toggle="yes">World J. Surg. Oncol.</italic><bold>22</bold> (1), 259. 10.1186/s12957-024-03539-7 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12957-024-03539-7</pub-id><pub-id pub-id-type="pmcid">PMC11439211</pub-id><pub-id pub-id-type="pmid">39342349</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sato</surname><given-names>A</given-names></name><etal/></person-group><article-title>Circulating tumor DNA harboring the BRAFV600E mutation May predict poor outcomes of primary papillary thyroid cancer patients</article-title><source>Thyroid</source><year>2021</year><volume>31</volume><issue>12</issue><fpage>1822</fpage><lpage>1828</lpage><pub-id pub-id-type="doi">10.1089/thy.2021.0267</pub-id><pub-id pub-id-type="pmid">34541884</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Sato, A. et al. Circulating tumor DNA harboring the BRAFV600E mutation May predict poor outcomes of primary papillary thyroid cancer patients. <italic toggle="yes">Thyroid</italic><bold>31</bold> (12), 1822&#8211;1828. 10.1089/thy.2021.0267 (2021).<pub-id pub-id-type="pmid">34541884</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/thy.2021.0267</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parvathareddy</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Evaluating the influence of hashimoto&#8217;s thyroiditis on clinico-pathological characteristics and prognostic outcomes of middle Eastern differentiated thyroid carcinoma</article-title><source>Int. J. Endocrinol.</source><year>2024</year><volume>2024</volume><fpage>9929782</fpage><pub-id pub-id-type="doi">10.1155/2024/9929782</pub-id><pub-id pub-id-type="pmid">39309476</pub-id><pub-id pub-id-type="pmcid">PMC11416175</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Parvathareddy, S. K. et al. Evaluating the influence of hashimoto&#8217;s thyroiditis on clinico-pathological characteristics and prognostic outcomes of middle Eastern differentiated thyroid carcinoma. <italic toggle="yes">Int. J. Endocrinol.</italic><bold>2024</bold>, 9929782. 10.1155/2024/9929782 (2024). Published 2024 Sep 14.<pub-id pub-id-type="pmid">39309476</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2024/9929782</pub-id><pub-id pub-id-type="pmcid">PMC11416175</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donnici</surname><given-names>A</given-names></name><etal/></person-group><article-title>Coexistence of hashimoto&#8217;s thyroiditis in differentiated thyroid cancer: post-operative monitoring of anti-thyroglobulin antibodies and assessment of treatment response</article-title><source>Diagnostics (Basel)</source><year>2024</year><volume>14</volume><issue>2</issue><fpage>166</fpage><pub-id pub-id-type="doi">10.3390/diagnostics14020166</pub-id><pub-id pub-id-type="pmid">38248043</pub-id><pub-id pub-id-type="pmcid">PMC10814696</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Donnici, A. et al. Coexistence of hashimoto&#8217;s thyroiditis in differentiated thyroid cancer: post-operative monitoring of anti-thyroglobulin antibodies and assessment of treatment response. <italic toggle="yes">Diagnostics (Basel)</italic>. <bold>14</bold> (2), 166. 10.3390/diagnostics14020166 (2024).<pub-id pub-id-type="pmid">38248043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics14020166</pub-id><pub-id pub-id-type="pmcid">PMC10814696</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>I</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HK</given-names></name><name name-style="western"><surname>Soh</surname><given-names>EY</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name></person-group><article-title>The association between chronic lymphocytic thyroiditis and the progress of papillary thyroid cancer</article-title><source>World J. Surg.</source><year>2020</year><volume>44</volume><issue>5</issue><fpage>1506</fpage><lpage>1513</lpage><pub-id pub-id-type="doi">10.1007/s00268-019-05337-9</pub-id><pub-id pub-id-type="pmid">31915977</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Lee, I., Kim, H. K., Soh, E. Y. &amp; Lee, J. The association between chronic lymphocytic thyroiditis and the progress of papillary thyroid cancer. <italic toggle="yes">World J. Surg.</italic><bold>44</bold> (5), 1506&#8211;1513. 10.1007/s00268-019-05337-9 (2020).<pub-id pub-id-type="pmid">31915977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00268-019-05337-9</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giovanella</surname><given-names>L</given-names></name><etal/></person-group><article-title>Thyroglobulin measurement is the most powerful outcome predictor in differentiated thyroid cancer: a decision tree analysis in a European multicenter series</article-title><source>Clin. Chem. Lab. Med.</source><year>2024</year><volume>62</volume><issue>11</issue><fpage>2307</fpage><lpage>2315</lpage><pub-id pub-id-type="doi">10.1515/cclm-2024-0405</pub-id><pub-id pub-id-type="pmid">38706105</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Giovanella, L. et al. Thyroglobulin measurement is the most powerful outcome predictor in differentiated thyroid cancer: a decision tree analysis in a European multicenter series. <italic toggle="yes">Clin. Chem. Lab. Med.</italic><bold>62</bold> (11), 2307&#8211;2315. 10.1515/cclm-2024-0405 (2024).<pub-id pub-id-type="pmid">38706105</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/cclm-2024-0405</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Barrio, M. J. et al. Pre-operative thyroglobulin measurement for thyroid cancer risk of recurrence and response to therapy. <italic toggle="yes">Am. J. Surg.</italic><bold>3</bold>, 236. 10.1016/j.amjsurg.2024.115818 (2024).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjsurg.2024.115818</pub-id><pub-id pub-id-type="pmid">39004566</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>